BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26345385)

  • 1. Overexpression of miRNA-497 inhibits tumor angiogenesis by targeting VEGFR2.
    Tu Y; Liu L; Zhao D; Liu Y; Ma X; Fan Y; Wan L; Huang T; Cheng Z; Shen B
    Sci Rep; 2015 Sep; 5():13827. PubMed ID: 26345385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo monitoring of angiogenesis inhibition via down-regulation of mir-21 in a VEGFR2-luc murine breast cancer model using bioluminescent imaging.
    Zhao D; Tu Y; Wan L; Bu L; Huang T; Sun X; Wang K; Shen B
    PLoS One; 2013; 8(8):e71472. PubMed ID: 23951172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
    Li X; Wang X; Ye H; Peng A; Chen L
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Norcantharidin inhibits tumor angiogenesis via blocking VEGFR2/MEK/ERK signaling pathways.
    Zhang L; Ji Q; Liu X; Chen X; Chen Z; Qiu Y; Sun J; Cai J; Zhu H; Li Q
    Cancer Sci; 2013 May; 104(5):604-10. PubMed ID: 23363445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway.
    Zhang Q; Lu S; Li T; Yu L; Zhang Y; Zeng H; Qian X; Bi J; Lin Y
    J Exp Clin Cancer Res; 2019 Apr; 38(1):173. PubMed ID: 31023337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer.
    Lian L; Li XL; Xu MD; Li XM; Wu MY; Zhang Y; Tao M; Li W; Shen XM; Zhou C; Jiang M
    BMC Cancer; 2019 Feb; 19(1):183. PubMed ID: 30819137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNAs modulating angiogenesis: miR-129-1 and miR-133 act as angio-miR in HUVECs.
    Soufi-Zomorrod M; Hajifathali A; Kouhkan F; Mehdizadeh M; Rad SM; Soleimani M
    Tumour Biol; 2016 Jul; 37(7):9527-34. PubMed ID: 26790441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-195 targets VEGFR2 and has a tumor suppressive role in ACHN cells via PI3K/Akt and Raf/MEK/ERK signaling pathways.
    Sun P; Wang L; Lu Y; Liu Y; Li L; Yin L; Zhang C; Zhao W; Shen B; Xu W
    Int J Oncol; 2016 Sep; 49(3):1155-63. PubMed ID: 27572273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C.
    Hu J; Cheng Y; Li Y; Jin Z; Pan Y; Liu G; Fu S; Zhang Y; Feng K; Feng Y
    Eur J Cancer; 2014 Sep; 50(13):2336-50. PubMed ID: 25001183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-195 Inhibits Tumor Progression by Targeting RPS6KB1 in Human Prostate Cancer.
    Cai C; Chen QB; Han ZD; Zhang YQ; He HC; Chen JH; Chen YR; Yang SB; Wu YD; Zeng YR; Qin GQ; Liang YX; Dai QS; Jiang FN; Wu SL; Zeng GH; Zhong WD; Wu CL
    Clin Cancer Res; 2015 Nov; 21(21):4922-34. PubMed ID: 26080838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
    Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
    Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dioscin inhibits colon tumor growth and tumor angiogenesis through regulating VEGFR2 and AKT/MAPK signaling pathways.
    Tong Q; Qing Y; Wu Y; Hu X; Jiang L; Wu X
    Toxicol Appl Pharmacol; 2014 Dec; 281(2):166-73. PubMed ID: 25111127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myricetin Inhibits Breast Tumor Growth and Angiogenesis by Regulating VEGF/VEGFR2 and p38MAPK Signaling Pathways.
    Zhou Z; Mao W; Li Y; Qi C; He Y
    Anat Rec (Hoboken); 2019 Dec; 302(12):2186-2192. PubMed ID: 31266091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes.
    Lang SA; Schachtschneider P; Moser C; Mori A; Hackl C; Gaumann A; Batt D; Schlitt HJ; Geissler EK; Stoeltzing O
    Mol Cancer Ther; 2008 Nov; 7(11):3509-18. PubMed ID: 19001434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells.
    Würdinger T; Tannous BA; Saydam O; Skog J; Grau S; Soutschek J; Weissleder R; Breakefield XO; Krichevsky AM
    Cancer Cell; 2008 Nov; 14(5):382-93. PubMed ID: 18977327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slit2 Promotes Angiogenic Activity Via the Robo1-VEGFR2-ERK1/2 Pathway in Both In Vivo and In Vitro Studies.
    Li S; Huang L; Sun Y; Bai Y; Yang F; Yu W; Li F; Zhang Q; Wang B; Geng JG; Li X
    Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5210-7. PubMed ID: 26244297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiRNA-575 suppresses angiogenesis by targeting Rab5-MEK-ERK pathway in endothelial cells.
    Zhao X; Yi Y; Meng C; Fang N
    Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30333257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CircCRIM1 Ameliorates Endothelial Cell Angiogenesis in Aging through the miR-455-3p/Twist1/VEGFR2 Signaling Axis.
    Zhao L; Chen R; Qiu J; Huang Y; Lian C; Zhu X; Cui J; Wang S; Wang S; Hu Z; Wang J
    Oxid Med Cell Longev; 2022; 2022():2062885. PubMed ID: 36254231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brucine, an indole alkaloid from Strychnos nux-vomica attenuates VEGF-induced angiogenesis via inhibiting VEGFR2 signaling pathway in vitro and in vivo.
    Saraswati S; Agrawal SS
    Cancer Lett; 2013 May; 332(1):83-93. PubMed ID: 23348691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.